

13TH AIS Antibody **2025** Industrial Symposium

JUNE 25-26 2025
TOURS, FRANCE

Post-Event Report

OUR STORY

In order to provide to the scientists involved in research on therapeutic antibodies, a comprehensive view about topics of interest for the pharmaceutical industry the LabEx MAbImprove started the **Antibody Industrial Symposium** in 2013.

Here are the previous editions:

1st Antibody Industrial Symposium (AIS2013) - May 28 in Tours, 2013 - *“Antibody Biosimilars”*

2nd Antibody Industrial Symposium (AIS2014) – July 3 in Montpellier, 2014 - *“MABDosing”*

3rd Antibody Industrial Symposium (AIS2015) – July 2 in Tours, 2015 - *“MABDelivery”*

4th Antibody Industrial Symposium (AIS2016) – July 4-5 in Montpellier, 2016 - *“Current and Next Generation Antibody Formats”*

5th Antibody Industrial Symposium (AIS2017) – June 27-28 in Tours, 2017
“ADCs – Design & Development for Therapy and Imaging in and beyond Cancer”

6th Antibody Industrial Symposium (AIS2018) – June 25-26 in Montpellier, 2018
“TARGETS FOR MABS: Innovative Approaches for their Discovery & Validation”

7th Antibody Industrial Symposium (AIS2019) – June 24-25 in Tours, 2019
“Harnessing the Immune System with Therapeutic Antibodies”

8th Antibody Industrial Symposium (AIS2020) – November 23-24 2020, **Virtual format**
“Multispecific Antibodies, Ab-like Molecules & Adoptive Cell Therapy for Fighting Diseases”

9th AIS (AIS2021) – June 22-25 2021, **Virtual format**

10th AIS(AIS2022) – June 28-29 in Montpellier, 2022 – **ANNIVERSARY EDITION**

11th AIS(AIS2023) – June 22-23 in Tours, 2022 – *Parallel Tracks on therapeutic Abs and Cell & Gene Therapy*

12th AIS(AIS2024) – June 20-21 in Montpellier, 2024 – *Next generation of Abs & New modalities*


13th AIS(AIS2025) – June 25-26 in Tours, 2025 – *Discovery & Optimization of Abs and derivatives, Next-Gen*

SAVE THE DATE



Since the 4th edition of AIS2016, MabDesign has joined forces in the organization of this congress, bridging academia and industry. Since 13 years, the AIS has allowed to gather more than **4130+ Participants** from **23 different countries**, **553+ Expert Speakers**, held **4070+ B2B meetings**, presented **115 Pitches**, **415+ posters** and **333 Exhibitors/Sponsors** showcase their latest innovations, in the field of therapeutic antibodies, recombinant proteins and other biotherapeutics research and development.




KEY FIGURES



13TH AIS2025

JUNE 25-26 2025

TOURS, FRANCE



400 Participants



50 Sponsors/Exhibitors



68 Posters



460 B2B Meetings



66 Speakers




20 Countries


WHO ATTENDED IN 2025 ?

KEY FIGURES

- ✓ **400+** participants from 23 different countries
- ✓ **460+** BtoB meetings took place
- ✓ **202+** different organizations present
- ✓ **50** Exhibitors and Sponsors
- ✓ **66** High-profile Speakers
- ✓ **68** Poster presentations



WHERE FROM?



2025 SPONSORS & EXHIBITORS

sanofi

ADVANCED INSTRUMENTS

ABZENA

ARDENA

BRUKER
Biosensors

GenScript
Make Research Easy

Kimialys

M mAbs
ANTIBODIES FOR MEDICINE

LYO-X
PK/PD AND SYSTEMS PHARMACOLOGY FOR BIOTHERAPEUTICS

QUALITY ASSISTANCE
Contract Research Organisation

SB Sino Biological

TWIST
BIOSCIENCE

WuXi Biologics
Global Solution Provider

Promega

BIOINTRON

IDT
INTEGRATED DNA TECHNOLOGIES

LiveDrop

BIOSYSTEMS ACRO

Benchling

SARTORIUS

PROTEIGENE

GENEWIZ
From Azenta Life Sciences

MCE
MedChemExpress

BIOTEM
Custom antibodies & services

KYMOS GROUP

Mabq

Agro-Bio

LGC

DELTA
LIFE SCIENCE

euofins
DiscoverX

GENOVIS

rapid novor

charles river

MAbSilico
Disruption Antibody Development

BIO-RAD

TERANGA GROUPE

BIOCAIR

Artimmune

Deeptope
Advanced antibody expertise

CORTALIX

CEGAV

sphere bio
work small, think big

revvity

PEPPERPRINT
A NEW DIVERSITY

RD-Biotech

HYBRIGENICS SERVICES

REAL RESEARCH

MaxCyte

BE4S
BIO-EXPERTS FOR SUCCESS

2025 INSTITUTIONAL & MEDIA PARTNERS

ANTIBODY SOCIETY

ariis
Alliance Recherche Industrie Santé

ASE BIO

Cancéropôle grand ouest

CLARA
CANCÉROPOLE LYON AUVERGNE RHÔNE - ALPES

FITC
Société Française d'Immuno-Thérapie du Cancer

iGEM

La gazette DU LABORATOIRE

PARIS-SACLAY CANCER CLUSTER
FRANCE INNOVATION CANCER

THE 2025 AGENDA

DAY 1

Wednesday, June 25th 2025

8h00 Registration and welcome coffee

8h40 Welcome Address - *Descartes Auditorium*

8h50 **OPENING KEYNOTE LECTURES** - *Descartes Auditorium*

8h50 • **Radioconjugates: Bridging Innovation with Industrial Feasibility**



Elsa Kress
Head of Business Development
MabDesign, France

9h00 • **Advances in Multispecific Antibody Development**



Paul W.H.I Parren
Board Chair
The Antibody Society, USA
Chief Scientific Officer
Gyes BV, Netherlands
Professor
Leiden University Medical Center, Netherlands

9h30 • **Biomarkers of response and resistance to ADCs across solid tumors**



Barbara Pistilli
MD, Chair of the Breast Cancer Unit
Gustave Roussy, France

10h00 Coffee Break at Exhibition Hall

10h30 **Discovery and optimization of Ms/Bs Abs, ADCs, Immunocytokines, and Next-Gen anti-PD-1**

- *Descartes Auditorium*

10h30 • **Bispecific antibodies engaging the adaptive and innate immune systems via CD28 and CD47 targeting**



Walter Ferlin
CSO


Antibody development against challenging targets such as GPCR, channels, etc

- *Pasteur Room*

10h30 • **Targeting gonadotropin receptors with single domain antibodies to control reproduction and treat associated dysfunctions**



Eric Reiter
DR1, PhD, Deputy director of UMR PRC, BIOS team
MUSCA team (INRIA/INRAE/CNRS), INRAE Centre Val de Loire, Nouzilly, France



THE 2025 AGENDA

Light Chain Bioscience, Switzerland

11h00 • **Lusvertikimab, a first-in-class IL7 receptor antagonist, in moderate to severe ulcerative colitis: results of a multicenter, randomized, placebo-controlled phase II study (CoTikiS)**



Silvia Comis
Chief Clinical and Medical Research Officer
 OSE Immunotherapeutics, France

11h30 • **Boosting CD3-Targeting Bispecific Antibodies: Exploring Synergistic Combination Partners**



Abdullah Elsayed
Group Leader
 Philochem AG, Switzerland/ Italy

12h00 • **Accelerating Drug Discovery Using AI-Enhanced Advanced Antibody Development Platforms**



Yu-Chih Lin
Technical specialist
 Sino Biological, Germany

12h10 • Lunch at Exhibition Hall

13h00 • **Workshop :Bridging Innovation to the Clinic: Smart First-in-Human Dose Selection for Novel Targeted Therapeutics**
 - PASTEUR ROOM



Lionel Renaud
PK/PD and Systems Pharmacology Modeler
 LYO-X, Switzerland



Saeed Masroor
Scientist in Quantitative Systems Pharmacology
 LYO-X, Switzerland

11h00 • **A first in class anti-Follicle Stimulating Hormone potentiating therapeutic antibody as a breakthrough treatment for fertility**




Elodie Kara
R&D Project Manager
 IGYXOS, France

11h30 • **Tiny but Mighty ! Single domain antibodies for cancer imaging and immunotherapies**




Patrick Chames
Team Leader Antibody Therapeutics and Immunotargeting
 Marseille Cancer Research Center, France

12h00 • **SPR-Based Platform for the Selection and Characterization of Therapeutic Monoclonal Antibodies Targeting Amyloid Aggregates**



Claude Nogues
CSO & Co-founder
 Kimialys, France



THE 2025 AGENDA

14h00

Discovery and optimization of Ms/Bs Abs, ADCs, Immunocytokines, and Next-Gen anti-PD-1

- Descartes Auditorium

14h00 • **TUB-040, a Napi2b-targeting ADC currently tested in clinical trials, shows long-lasting anti-tumor efficacy via Topoisomerase-I inhibition and excellent tolerability**



Björn Hock
Chief Development Officer
Tubulis, Germany

14h30 • **INA03: A potent transferrin-competitive ADC against CD71 for safer Acute Leukemia treatment. How to transform a undruggable to a druggable target**



Pierre Launay
CSO
Inatherys, France

15h00 • **Enhancing Mab and BsAb Discovery: From Strategic Design to Fit-for-Purpose Screening and Characterization**



Winfried Elis
Senior BD Manager
Wuxi Biologics CRO Services, Germany

15h15 • **The role of developability as part of successful bioconjugate lead candidate selection**



Rob Holgate
Vice-President, Research and Innovation
ABZENA, UK

15h40

Coffee Break at Exhibition Hall

Challenges and opportunities in alternative delivery approaches

- Pasteur Room

14h00 • **A multidisciplinary perspective on subcutaneous biologics delivery**



Sylvain Huille
BioPharmaceutics Development France
SANOFI, France

14h30 • **Topical Application of Nebulized Polyclonal IgG: from Proof of Concept into Clinical Development**



Anna Schnell
Senior Scientist

CSL Behring, Switzerland

15h00 • **VHH to treat brain disorders and how they can go through the BBB**




Philippe Rondard
Team Leader, Neuroreceptors: Dynamics and Functions
Institut de Génomique Fonctionnelle, France

15h30 • **From Delivery to Detection: Nanocarrier and Antibody Synergy in Advanced Therapy Development**



Foka Venema
Senior Scientist Project Manager
ARDENA, Netherlands



THE 2025 AGENDA

16h00

Pitch Session : Innovative Approaches and New trend Technologies

- Descartes Auditorium

16h00 • **Patient-Derived Lymphoma Spheroids as preclinical models for predicting patient responses to advanced therapies in B-NHL: example of glofitamab in follicular lymphoma**



Christine Bezombes

Research investigator

Centre de Recherches en Cancérologie de Toulouse, Toulouse, France

16h10 • **Development of pH-Modulated Antibodies, that Recognize Immune System Checkpoints**



Diego Barba

Medical Doctor

Montpellier Cancer Research Institute (IRCM), France

16h20 • **High-Sensitivity MAPPs for High-Confidence Immunogenicity Risk Assessment in Therapeutic Antibody Development**



Elise Pepermans

CEO & Co-founder

ImmuneSpec, Belgium

16h30 • **A Sustainable Droplet Microfluidic Platform for Fast Cross-Species Functional Antibody Discovery from Minimal Samples**



François Côte

Business Developer

CER Groupe, Belgium

16h40 • **Unlocking the Potential of Bispecific T-Cell Engagers: Pioneering HER3-Targeted Therapies for Cancer Treatment**



Giuseppe Roscilli

Chief Technology Officer and Dept Director

Takis Biotech, Italy

16h50 • **First-in-class anti-TRPV6 antibody as a new therapeutic agent in cancer**



Johanna Marines

Head of Preclinical Development

Mabqi, France

Effector cell redirection (heme/solid) - Pasteur Room

16h00 • **Harnessing NK cells for the treatment of cancer: update on NKp46 engagers**




Olivier Demaria

R&D Director

Innate Pharma, France

16h30 • **Developability Screening Cascade to Advance Multispecific Therapeutic Antibodies to the Clinic**




Cyrille Dreyfus

Associate Director

Ichnos Glenmark Innovation, Switzerland


17h00 • **MAIT engagers: Providing an effective therapeutic window to treat solid tumors**



Julie Prigent

Associate Director, R&D

Biomunex Pharmaceuticals, France



THE 2025 AGENDA

17h00 • *Smaller ADC formats based on Therano-Stick™ technology could make the difference for solid tumors!*



Meddy El Alaoui
CEO
AbTx, France

17h10 • *Microalgae-produced antibody as effective as those produced in mammalian cells*



Muriel Bardor
CEO & CSD
Alga Biologics, France

17h20 • *Unveiling the Pan-Cancer potential of dual-mechanistic uPAR-targeting ADCs across cancers*



Virginia Metrangolo


17h30 • **Poster Presentation Session - Announcement of "BEST POSTER" Prize**
- Exhibition Hall

Pitch in front of Investors - Private session
- Pasteur Room



19h00 • **Dinner Cocktail Reception at Exhibition Hall**

21h00 • End of DAY 1



DAY 2

Thursday, June 26th 2025

8h00 Welcome coffee

8h20 **Fc domains of mAbs, ADCs, and BsAbs : Potency, Safety, Regulatory & IP**

- Descartes Auditorium

Session Sponsored by



8h20 • **Fc-mediated functions modulation of mAbs, ADCs, BsAbs and Fc-fusion proteins**



Alain Beck

Senior Director, Biologics CMC & developability

Pierre Fabre, France

8h50 • **Still living in LALA land? Are there better ways to eliminate unwanted Fc effector functions?**



Geoff Hale

CEO

mAbsolve, UK

9h15 • **Studying structure/function relation of therapeutic antibodies using LC and MS**



Koen Sandra

CEO

RIC Group, Belgium

9h40 • **The confusing patent landscape regarding Fc domain domain engineering: ADCC, serum half life and more**



Ulrich Storz

Senior Partner - Patent Attorney


Michalski Huettermann, Germany

10h00 Coffee Break at Exhibition Hall

Biomarkers development for next-generation Antibodies treatments

- Pasteur Room

8h20 • **Clinical and molecular biomarkers for optimization cohorts in early-phase oncology trials**



Elisa Fontana

MD, PhD, Hospital Medical Director

Sarah Cannon Research Institute in London, UK

8h50 • **Molecular imaging to get insight into (modified) antibody behavior in patients**



Derk Jan de Groot

MD, PhD, Medical Oncologist

UMCG Universitair Medisch Centrum Groningen, The Netherlands

9h20 • **Navigating In-vitro Diagnostics Regulation (IVDR) frameworks in early drug development**



Rafael Grochot

MD, MSc, Medical Oncologist

Sarah Cannon Research Institute in London, UK


9h50 • **Writing the Future of Biologics with an Integrated Offering of Immunization, Libraries, and Machine Learning**



Leonie Alten

Staff, Scientific Development Scientists, SynBio


Twist Bioscience, USA



10h30


Non-conventional ADCs - Descartes Auditorium

10h30 • *Enhancing therapeutic index of antibody-drug conjugates through site-specific DAR1 conjugation*



Fabian Schlimpen
Senior Scientist
Syndivia, France

11h00 • *Antibody-Vincristine Conjugates as Potent Anticancer Therapeutic Agents*




Héloïse Cahuzac
Postdoctoral Researcher
BioFunctional Chemistry Team, University of Strasbourg, France

11h30 • *Antibody Fragment Drug Conjugates: Next-Generation ADCs Tailored for Solid Tumours*



Mahendra Deonarain
CEO
Antikor Biopharma Ltd, UK

12h00 • *ADC Affinity and Tissue Penetration: Tools for Comprehensive Characterization*



Stéphane Pinhal
Technical Sales Manager
Bruker Biosensors, Germany

12h10

Lunch at Exhibition Hall

Mechanisms of resistance to ADCs, ADA, and biomarker-driven versus payload resistance

- Pasteur Room

10h30 • *Novel Multi-Payload ADCs Assembled in One Step from Native Antibodies that Show Excellent Biophysical Properties and High Efficacy in vivo*




Philipp Spycher
Founder and CSO
Araris Biotech AG, Switzerland

11h00 • *Antibody Conjugates in Oncology and Beyond*




Christian Kunz
Vice President Biologics Discovery
Ridgeline Discovery, Switzerland

11h30 • *From Single Cell to Stable Clone: Optimizing Cell Line Development for Biotherapeutics*




Ludivine Aubignat
Reagent Sales Specialist EMEA
Advanced Instruments - Solentim, France

12h00 • *A comprehensive discovery and engineering workflow for developing innovative anti-Nectin-4 antibody drug conjugates*



Jacques Fieschi
CSO
MmAbs, France



THE 2025 AGENDA

13h00

Round Table "Comment évoluer grâce aux dispositifs de financement Nationaux et Européens "

- Pasteur Auditorium



Marie-Christine Maurel
Chief Scientific Officer & Founder
IGYXOS Biotherapeutics, France



Sylvain Yon
Chief Executive Officer
Mabqj, France



Julie Lellouche
Responsable Sectorielle Santé
Bpifrance, France



Roxane Brachet
National Contact Point Health
Ministère de l'Enseignement supérieur et de la Recherche



Pierre d'Epenoux
Chief Executive Officer
ImCheck Therapeutics, France




Guirec Cloarec
Innovation Project Manager
Mabdesign, France

14h00

AI-based Computational Approaches for Antibody Discovery & Optimization & Accelerate Clinical Trials

- Descartes Auditorium

14h00 • *In silico antibody discovery: rethinking the funnel-shape process*



Astrid Musnier
Co-founder & Head of Biology
MAbSilico, France

14h30 • *Revolutionizing immuno-oncology drug target discovery, through AI/ML predictive computational discovery platform Unigen*



Zoya Alteber
Director Research and drug Discovery

Emerging 3D preclinical models - Pasteur Room

14h00 • *Patient-Derived tumour Explants as a preclinical model system for predicting patient responses to advanced therapies*




Catrin Pritchard
Professor of Cancer Biochemistry
Leicester Cancer Research Centre, University of Leicester, UK

14h30 • *Hydrogel droplet microfluidic approach for high-throughput drug screening in spheroids*



Guillaume Mottet
Senior Director of Biologics Discovery
Microfluidics Team, SANOFI, France

15h00 • *In Vivo New Alternative Methods (NAMs) for Drug Evaluation: From Cancer Cell Line 3D Models to Patient Tumor Avatars*



THE 2025 AGENDA

Zoya Alteber

Director Research and drug Discovery

Compugen Ltd, Israel

15h00 • **Powering explainable AI to optimize biological prescriptions and drug development in IBD using real-world data**



Frédéric Parmentier

VP of Data Science

Ariana Pharma, France

15h30 • **Transforming Antibody Therapeutics: The Role of AI in Development and Engineering**



Robert Ford

Field Application Scientist (FAS)

GenScript Biotech, Netherlands

15h00 • **In Vivo New Alternative Methods (NAMs) for Drug Evaluation: From Cancer Cell Line 3D Models to Patient Tumor Avatars**



Jean Viallet

CEO

INOVOTION, France

15h40

Closing Keynote - Descartes Auditorium

15h40 • **The Rise of T Cell Engaging Antibodies**



Patrick A. Baeuerle

Co-Founder, Chief Scientific Advisor and Chairman of the SAB

Cullinan Therapeutics Inc., USA

Honorary Professor of Immunology

Institute for Immunology, Ludwig Maximilian University, Germany

16h10

Announcement of AIS2026

16h30

End of Congress

WORKSHOP by  **LYO-X** MULTI-SCALE SYSTEMS PHARMACOLOGY FOR BIOTHERAPEUTICS

Bridging Innovation to the Clinic: Smart First-in-Human Dose Selection for Novel Targeted Therapeutics
 June 25th 2025 at 13h00 in PASTEUR ROOM

Selecting the right first-in-human (FIH) dose is a critical step in translating groundbreaking therapies, such as antibody-drug conjugates (ADCs), bispecific antibodies, immunocytokines, gene therapies, antisense oligonucleotides (ASOs), Fc-fusion proteins, and combination therapies, into clinical success. Traditional dose selection approaches often fall short in addressing the unique pharmacokinetic (PK) and pharmacodynamic (PD) properties of these novel modalities, increasing the risk of suboptimal efficacy or safety concerns.


This workshop will **provide a practical overview of FIH dose selection challenges and solutions**, drawing from real-world examples and the latest modeling strategies. We will demonstrate how PK/PD modeling can integrate preclinical data, mechanistic insights, and translational approaches to optimize dose selection, de-risk early clinical trials, and support regulatory interactions. Beyond identifying a safe starting dose, PK/PD modeling can also predict clinically efficacious doses, time to onset of effect, and effect duration. In this way, FIH studies will not only be safe but feature an efficient dose escalation with an informed top dose and the right study duration, facilitating a seamless transition to dose-finding studies or even directly to Phase III.

Designed for scientists and decision-makers in preclinical and translational research, this session will offer a clear, strategic framework for using PK/PD modeling to inform FIH study design. Whether you are working on preclinical development, translational strategy, or regulatory interactions, you will leave with actionable insights to enhance decision-making in early-phase drug development.

Hosted by



Lionel Renaud
PK/PD and Systems Pharmacology Modeler
 LYO-X, Switzerland



Saeed Masroor
Scientist in Quantitative Systems Pharmacology
 LYO-X, Switzerland

Atelier par  **mabDesign**
THE BIOTHERAPY EXPERT

Comment évoluer grâce aux dispositifs de financement Nationaux et Européens
 June 26th 2025 at 13h00 in PASTEUR ROOM

Cette table ronde portera sur comment évoluer au travers des financements non-dilutifs, avec des intervenants opérants dans les dispositifs proposés aux niveaux national et européen pour accompagner les biotechs dans leurs projets d'innovation. Des témoignages d'entreprises ayant bénéficié d'aides publiques viendront enrichir les échanges, et un temps de questions/ réponses permettra d'ouvrir les débats.

Intervenants :



Marie-Christine Maurel
Chief Scientific Officer & Founder
 IGYXOS Biotherapeutics, France



Sylvain Yon
Chief Executive Officer
 Mabqi, France




Julie Lellouche
Responsable Sectorielle Santé
 Bpifrance, France



Roxane Brachet
National Contact Point Health
 Ministère de l'Enseignement supérieur et de la Recherche



























Pierre d'Epenoux
Chief Executive Officer
 ImCheck Therapeutics, France



Guirec Cloarec
Innovation Project Manager
 Mabdesign, France

2025 SCIENTIFIC ADVISORY BOARD

 <p>Pierre Fabre</p>			
<p>Alain Beck <i>Senior Director, Biologics CMC & developability</i> Centre d'Immunologie Pierre Fabre</p>		<p>Thierry Wurch <i>Senior Director, Global External Innovation and Partnering in Oncology</i> Evotec</p>	
			
<p>Ana Antunes <i>Head of International Affairs, Scientific Events & Communication</i> MabDesign</p>		<p>Nicolas Poirier <i>Chief Executive Officer</i> OSE Immunotherapeutics</p>	
			
<p>Lennart Zabeau <i>Principal Scientist</i> Orionis Biosciences, Belgium</p>		<p>Stéphanie Cornen <i>Senior Director, Head of Portfolio Strategy</i> Innate Pharma</p>	
			
<p>Francis Duffieux <i>Principal Scientist, Head of Protein Purification, LMR Vitry</i> SANOFI</p>		<p>Elisa Fontana <i>MD, PhD, Hospital Medical Director</i> Sarah Cannon Research Institute, UK</p>	
			
<p>Eric Reiter <i>DR1, PhD, Deputy director of UMR PRC, BIOS team</i> MUSCA team (INRIA/INRAE/CNRS), INRAE Centre Val de Loire, Nouzilly, France</p>		<p>Stefan Zielonka <i>Prof. Dr., Global Head of Antibody Discovery & Protein Engineering (ADPE)</i> Merck Healthcare KGaA, Darmstadt, Germany</p>	
			
<p>Nathalie Corvaia <i>CEO</i> NCO Biotech Consulting, France</p>		<p>Pierre Ferré <i>VP Preclinical Development</i> Compugen Ltd., Israel</p>	

Join us in 2026



3rd Innovations for Cell and Gene Therapies Congress (ICGT2026)

27-28 May 2026 in SANOFI Campus Gentilly, France

Laure Delhon

+33 (0)7 69 85 65 56

laure.delhon@mabdesign.fr



14th Antibody Industrial Symposium (AIS2026)

30 June - 1 July 2026 in Montpellier, France

Ana Antunes

+33 (0)7 59 56 52 76

ana-sofia.antunes@mabdesign.fr



11th Bioproduction Congress (BIOPC2026)

September 2026 in Lyon, France

Pierre-Mehdi Hammoudi

+33 (0)4 78 02 39 89

pierre-mehdi.hammoudi@mabdesign.fr



10th Immunotherapies & Innovations for Infectious Diseases Congress (I4ID2026)

November 2026 in Lyon, France

Laure Delhon

+33 (0)7 69 85 65 56

laure.delhon@mabdesign.fr